A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function

Author(s):
Slingerland, M.; Hess, D.; Clive, S.; Sharma, S.; Sandstrom, P.; Loman, N.; Porro, M.G.; Mu, S.; Waldron, E.; Valera, S.Z.; Gelderblom, H.
Published
2014
Publication type
Article / Letter to editor
PanobinostatHepatic impairmentPan-deacetylase inhibitorHistonePhase I
Date issued
2014-11-30
Language
English
Is part of
Cancer Chemotherapy and Pharmacology (2014), Vol. 74, no. 5, p. 1089-1098
hdl
1887/104644
doi
10.1007/s00280-014-2594-6